Search research articles
Contact Us
Filters
Showing results (451-460 of 703) with videos related to
Page
of 71
Sort By:
Annals of Surgical Oncology
|
August 4, 2021
Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
Andrew T Li, Kavita Vakharia, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 12, 2024
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
Ines Pires da Silva, Isabel Li, Selma Ugurel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Communications Medicine
|
October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Judith M Versluis, Huma Shehwana, Robert Elens, et al.
Future Oncology (London, England)
|
December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
Jason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Nature Medicine
|
January 4, 2024
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Cell
|
August 11, 2018
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Future Oncology (London, England)
|
February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
Jason J Luke, Georgina V Long, Caroline Robert, et al.
The Journal of Investigative Dermatology
|
February 18, 2019
Molecular Genomic Profiling of Melanocytic Nevi
Andrew J Colebatch, Peter Ferguson, Felicity Newell, et al.
Page
of 71
Search research articles
Search
Showing results (451-460 of 703) with videos related to
Sort By:
Page
of 71
Annals of Surgical Oncology
|
August 4, 2021
Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
Andrew T Li, Kavita Vakharia, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 12, 2024
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
Ines Pires da Silva, Isabel Li, Selma Ugurel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Communications Medicine
|
October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Judith M Versluis, Huma Shehwana, Robert Elens, et al.
Future Oncology (London, England)
|
December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
Jason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Nature Medicine
|
January 4, 2024
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Cell
|
August 11, 2018
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Future Oncology (London, England)
|
February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
Jason J Luke, Georgina V Long, Caroline Robert, et al.
The Journal of Investigative Dermatology
|
February 18, 2019
Molecular Genomic Profiling of Melanocytic Nevi
Andrew J Colebatch, Peter Ferguson, Felicity Newell, et al.
Page
of 71